Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 3
2019 10
2020 6
2021 6
2022 2
2023 4
2024 11
2025 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R; FLOW Trial Committees and Investigators. Perkovic V, et al. N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24. N Engl J Med. 2024. PMID: 38785209 Clinical Trial.
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.
Perkovic V, Barratt J, Rovin B, Kashihara N, Maes B, Zhang H, Trimarchi H, Kollins D, Papachristofi O, Jacinto-Sanders S, Merkel T, Guerard N, Renfurm R, Hach T, Rizk DV; APPLAUSE-IgAN Investigators. Perkovic V, et al. N Engl J Med. 2025 Feb 6;392(6):531-543. doi: 10.1056/NEJMoa2410316. Epub 2024 Oct 25. N Engl J Med. 2025. PMID: 39453772 Clinical Trial.
Two Pilgrims.
Helvacı Ö. Helvacı Ö. Am J Kidney Dis. 2019 Nov;74(5):A13-A14. doi: 10.1053/j.ajkd.2019.07.003. Am J Kidney Dis. 2019. PMID: 31653314 No abstract available.
Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study.
Kavanagh D, Bomback AS, Vivarelli M, Nester CM, Remuzzi G, Zhao MH, Wong EKS, Wang Y, Krishnan I, Schuhmann I, Trapani AJ, Webb NJA, Meier M, Israni RK, Smith RJH; APPEAR-C3G investigators. Kavanagh D, et al. Lancet. 2025 Oct 11;406(10512):1587-1598. doi: 10.1016/S0140-6736(25)01148-1. Epub 2025 Sep 25. Lancet. 2025. PMID: 41016405 Free article. Clinical Trial.
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis.
Rossing P, Bakris G, Perkovic V, Pratley R, Tuttle KR, Mahaffey KW, Idorn T, Belmar N, Bosch-Traberg H, Rasmussen S, Busch RS, Schmieder RE, Gillard P, Mann JFE; FLOW Investigator Group. Rossing P, et al. Diabetes Care. 2025 Nov 1;48(11):1878-1887. doi: 10.2337/dc25-0472. Diabetes Care. 2025. PMID: 40730031 Free PMC article. Clinical Trial.
Another Victim of Rapid Weight Loss?
Helvaci O, Korucu B, Arinsoy T. Helvaci O, et al. Kidney Int Rep. 2019 Jan 23;4(4):633. doi: 10.1016/j.ekir.2019.01.007. eCollection 2019 Apr. Kidney Int Rep. 2019. PMID: 30993242 Free PMC article. No abstract available.
Low Copeptin Levels in Patients With Intradialytic Hypotension.
Korucu B, Helvaci O, Ozbas B, Yeter H, Yuce D, Elbeg S, Derici U. Korucu B, et al. Among authors: helvaci o. Ther Apher Dial. 2019 Oct;23(5):460-466. doi: 10.1111/1744-9987.12784. Epub 2019 Feb 1. Ther Apher Dial. 2019. PMID: 30549206
49 results